CLAIMS

5

10

25

- 1. A peptide-lipid complex in an aqueous solution, characterised in that said lipid is a bilayer-forming galactolipid material and that the weight ratio between the peptide and the galactolipid material is 1:5 1:50, with the proviso that the peptide is not LL-37.
- 2. The complex according to claim 1, wherein the weight ratio between the peptide and the galactolipid material is 1:10 1:50.
- 3. The complex according to claim 1 or 2, wherein said peptide is a charged and amphiphilic peptide having a molecular weight below 30 kDa.
- 4. The complex according to any of claims 1-3, wherein the peptide has at least four positively charged amino acids.
 - 5. The complex according to any of claims 1-4, wherein the peptide is in the form of a pharmaceutically acceptable salt.
- 20 6. The complex according to any of claims 1-5, wherein the galactolipid material is a polar lipid mixture rich in digalactosyldiacylglycerols.
 - 7. The complex according to any of claims 1-6, wherein the galactolipid material is CPL-Galactolipid.
 - 8. The complex according to any of claims 1-7, wherein the peptide is an apolipoprotein or an apolipoprotein analogue.
- 9. The complex according to any of claims 1-7, wherein the peptide is selected from the group consisting of insulin, glucagon, erythropoietin, darbepoietin, streptokinase, somatropin, desmopressin, oxytocin, gonadorelin, nafarelin, octreotid, lanreotid, ganirelix, cetrorelix, teriparalid, and salmon calcitonin.

- 10. The complex according to any of claims 1-7, wherein the peptide is selected from the group consisting of magainin 2, cecropin, and histatin.
- 11. The complex according to any of claims 1-7, wherein said peptide is a cationic antimicrobial peptide having a molecular weight of 2.5 5 kDa.
 - 12. The complex according to any of claims 1-7 and 11, having a peptide:galactolipid weight ratio of 1:10 1:27.
- 13. The complex according to any of claims 1-7, 11 and 12, wherein the peptide is selected from the group consisting of LL-25, LL-26, LL-27, LL-28, LL-29, LL-30, LL-31, LL-32, LL-33, LL-34, LL-35, LL-36, and LL-38.
- 14. The complex according to any of claims 1-7, and 11-13, comprising the peptide LL-25 and a galactolipid material.
 - 15. A colloidal solution of a complex according to any of claims 1-14, wherein the mean size of said complexes is below 100 nm.
- 16. A colloidal solution of a complex between LL-37 and a bilayer-forming galactolipid material, wherein the mean size of said complexes is below 100 nm.
 - 17. A colloidal solution of a complex according to claim 15 or 16 for use as a medicament.

25

30

- 18. A method of preparing a colloidal solution according to claim 15 or 16, characterized in the following steps:
- (i) weighing of the galactolipid material as a dry, free-flowing powder in an appropriate container, e.g. a flask made of borosilicate glass or polypropylene plastic, to a final concentration of 1 to 5 mg/g, which container allows for a headspace which is equal to or larger than the final volume of the solution;
- (ii) selecting an aqueous medium with an ionic strength >100 mM and an appropriate pH, normally in the range of 4 to 10 but preferably around 7;

WO 2005/079860 PCT/SE2005/000252

- (iii) weighing of the peptide in another appropriate container, e.g. a flask made of borosilicate glass or polypropylene plastic, and adding the selected aqueous medium to a peptide concentration corresponding to a final weight ratio between the peptide and galactolipid material of 1:5 to 1:50;
 - (iv) adding the peptide solution (iii) to the dry galactolipid material (i);
- (v) shaking the mixture from (iv) vigorously at room temperature using a suitable shaker at high speed for at least 1 h or until the mixture has become clear; and
 - (vi) equilibrating the resulting collodial solution.
- 19. Use of a colloidal solution of a complex according to any of claims 1-16 for the manufacture of a medicament.
- 20. Use of a colloidal solution of a complex according to claim 15 or 16 for the manufacture of a medicament for treatment of infections, wound healing or other diseases with a deficiency in antimicrobial activity.
- 21. Use of a colloidal solution of a complex according to claim 20 for the
 manufacture of a medicament for topical treatment of infections, wounds, atopic
 eczema and other conditions deficient in antimicrobial activity and/or
 angiogenesis.

5

10